<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="165107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948493</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-100-OL</org_study_id>
    <nct_id>NCT00948493</nct_id>
  </id_info>
  <brief_title>Treatment Use of Generex Oral-lyn™ in Patients With Diabetes</brief_title>
  <official_title>An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn™ in Patients With Type 1 or Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Generex Biotechnology Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Generex Biotechnology Corp.</source>
  <brief_summary>
    <textblock>
      The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients
      with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory
      alternative therapy available for treatment of diabetes, and who are not eligible to
      participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This protocol is
      intended as a substitute for the Single Patient IND mechanism to obtain Generex Oral-lyn™.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buccal insulin spray</intervention_name>
    <description>Oral insulin spray absorbed in buccal mucosa</description>
    <other_name>Generex Oral-lynTM (oral, buccal insulin spray)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study is closed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 18, 2013</lastchanged_date>
  <firstreceived_date>July 27, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
